Publications

Members only publications are marked with a lock icon:
Filter By
Health Policy
June 21, 2019

On June 17, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule  that would update the Part D e-prescribing program by adopting standards that ensure secure transmissions and expedite prior authorizations.

Under the proposed change, clinicians would be able to choose to complete prior authorizations online, reducing burden for...

Health Policy
June 21, 2019

The Centers for Medicare & Medicaid Services (CMS) is accepting Notices of Intent to Apply (NOIAs) via the Accountable Care Organization Management System (ACO-MS) for a January 1, 2020, start date. You must submit a NOIA if you intend to apply to the BASIC or ENHANCED track of the Medicare Shared Savings Program, for a Skilled Nursing Facility (SNF) 3-Day Rule Waiver, and/or to establish and operate a Beneficiary Incentive Program:

  • NOIA submissions are due no later than June 28 at noon ET
  • A NOIA submission does
  • ...
Health Policy
June 21, 2019

The Centers for Medicare & Medicaid Services (CMS) has contracted with Guidehouse to conduct data validation and audits of a select number of Merit-based Incentive Payment System (MIPS) eligible clinicians.  Data validation and audits are processes that will help ensure MIPS is operating with accurate and useful data. MIPS-eligible clinicians, groups, and virtual groups are required by regulation to comply with data-sharing requests, providing all data as requested by CMS.

If you are selected for data validation and/or audit, you will receive a request for information from...

JAMDA
June 20, 2019

We developed an instrument to assess nursing home residents' quality of life (QOL), with a focus on QOL-related factors modifiable through nursing home care, within the South Korean context; then, we tested its validity and reliability.

JAMDA
June 20, 2019

Sarcopenia is a disease characterized by a progressive loss of skeletal muscle mass and strength and is related to physical impairment, disability, worse clinical outcomes, and mortality in all health care settings.1 An important fact is that it is also reversible, with tailored exercise and nutritional support.1,2 Sarcopenia prevalence varies widely depending on the criteria, measurement methods, and cut-off points used for its assessment1,2; to date, few studies addressed the issue of sarcopenia in hospitalized older patients, rendering it an under-recognized clinical entity.

JAMDA
June 20, 2019

To describe the sociodemographic, clinical, and treatment characteristics of people who are comatose in Canadian complex continuing care (CCC) and long-term care (LTC) settings, and to make recommendations to promote comprehensive care planning for this population.

JAMDA
June 18, 2019

Paratonia, a form of hypertonia typically seen in dementia, is often associated with difficulties in positioning and daily care. No evidence-based therapy or clinical guideline for management is available. In this study, the short-term effect of harmonic techniques (HT) and supporting cushions (SC) on paratonia was explored.

JAMDA
June 18, 2019

Previous studies in older populations have shown a cardioprotective effect for obesity, an observation known as the obesity paradox. However, whether a decrease or increase in body weight over a certain period affects disability and mortality in older adults remains unknown. Hence, we examined whether the percent body weight change can predict the risk of mortality and disability in older Japanese adults.

JAMDA
June 18, 2019

The accuracy of data is vital to identifying hospitalization outcomes for clinical trials. Patient attrition and recall bias affects the validity of patient-reported outcomes, and the growing prevalence of Medicare Advantage (MA) could mean Fee-for-Service (FFS) claims are less reliable for ascertaining hospital utilization. Statewide health information exchanges (HIEs) may be a more complete data source but have not been frequently used for research.

JAMDA
June 18, 2019

To determine whether the trajectory of preclinical lap time variability from a 400-m walk differentiates participants with future mild cognitive impairment (MCI)/Alzheimer's disease (AD) from matched controls.